How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
|
|
- Daniella Georgia Griffin
- 5 years ago
- Views:
Transcription
1 How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del Rocío Seville
2 Index - INTRODUCTION - FIRST LINE TREATMENT: * Fit patients * Non-Fit patients - REFRACTORY / RELAPSE TREATMENT - TAKE HOME MESSAGES
3 Mantle cell lymphoma Real world data Nordic Lymphoma Group observational study 5 % Years : 1389 patients 3,6% 2,4% 2 : 1 Abrahamsson et al Blood. 2014;124(8):
4 A subgroup of patients with MCL may be SAFELY OBSERVED from diagnosis Asymptomatic patients Non-nodal presentation Nodal low burden Low proliferative rate Abrisqueta et al, Ann Oncol Oct 1;28(10):
5 Treatment FIT PATIENTS (Autologous-SCT) NON- FIT PATIENTS (Comorbidities/Age)
6 Randomized trial INTERFERON vs ASCT after CHOP induction Progression free survival 17 m. 39 months ( CR 46 m. PR 33 m. ) Dreyling et al, Blood :
7 Pretransplant Induction Clinical trial Chemotherapy N RG / RC SG / SLP Geisler (NLG) (2008) Damon (CALGB) (2009) Maxi-CHOP x 3 + HADx 3 + R cycles 4º,5º,6º + AUTO-TPH (BEAM) Rituximab if PCR(+) R-CHOP-Mtx x 2 + VP16-AraC x 1 + CBV x 1 + AUTO-TPH + Rituximab x % / 54% 70% / 66% at 6 years 78 88% /69% 64% / 56% at 5 years Delarue (GELA) (2013) R-CHOP x 3 + R-DHAP x 3 + AUTO-TPH 60 82% / 78% 75% / 64% at 5 years - ALL seem to have SIMILAR TOXICITY (high, mainly Hematologic) and OUTCOME (1) - HyperCVAD-R probably is the most effective induction regimen (2), but toxicity seems to be higher (3) and is associated with higher rates of hematopoietic progenitor cell mobilization failure despite Plerixafor rescue (4) - BENDAMUSTINE-R could be a good induction regimen (5) (1) Bude et al, JCO 2011;29: (2) Romaguera et al JCO 23: (3) Merli et al British Journal H 56, (4) Salhotra et al, BBMT 23 (2017) (5) Chen et al BJH 2017, 176(5),
8 Autologous SCT Clinical Trials After CHOP: INTERFERON AUTO-SCT PreAUTO-SCT CHOP CHOP/DHAP PostAUTO-SCT Watch - Wait Consensus EBMT / European MCL Network INDUCTION must include CYTARABINE and RITUXIMAB Consolidate ALL candidates with AUTOLOGOUS Stem Cell Transplantation Robinson et al, Leukemia (2015) 29,
9 Hermine et al, 2016 PFS 5 years median PFS R-CHOP x 6 R-CHOP x 3 / DHAP-R x 3 AUTO - SCT AUTO - SCT n = 234 n = 232 Follow up 6 years 44 % 65 % 4,3 years 9,1 years No difference in OVERALL SURVIVAL Similar Bone Marrow Transplant-related Mortality > GRADE 3-4 TOXICITY with DHAP-R: Mainly Hematologic 65 % 4,3 y 9,1 y. 40 %
10 DHAP-R x 4 AUTO-TPH n = 299 n = 257 R n = 120 Observation n = 120 Follow up 4 years PFS: 83% OS: 89% PFS: 64% OS: 80% Progression-free Survival Overall Survival N Engl J Med 2017;377:
11 Treatment for FIT patients Hiper-CVAD MTX-AraC-R CALGB regimen Maxi-CHOP AraC-R CHOP-R DHAP-R AUTOLOGOUS SCT
12 NON-FIT PATIENTS (Comorbidities/Age)
13 1º Line Randomized Clinical Trials Overall Survival TTF PFS FCM FCM CHOP CHOP > OR > CR > TTF FC CHOP y INTERF V CHOP -CAP BENDA CHOP INCOMPLETE DATA SAFETY WARNING MAINTENANCE NECCESARY? FCM vs FCM-R. Forstpointner et al, Blood. 2004;104: CHOP vs CHOP-R. Lenz et al, J Clin Oncol 23: CHOP-R vs FC-R +/- R Kluin-N et al, N Engl J Med 2012;367: CHOP-R vs BENDA-R Rummel et al, Lancet 2013; 381: CHOP-R vs VR-CAP Robak et al, N Engl J Med 2015;372:944-53
14 Bendamustine results in 1º line Rm 2013 R- BENDA R-CHOP Phase 3 NO INFERIORITY Trial. INDOLENT lymphomas and MCL (n 541 patients) MANTLE CELL LYMPHOMA: 94 / 541 patients PFS TOXIC EFFECTS: - Less INFECTIONS - Less Peripheral neuropathy - Less Stomatitis, etc. 22,1 months 35,4 months Conclusion: Bendamustine plus rituximab can be considered as a preferred first-line treatment approach to R-CHOP CHOP-R vs BENDA-R Rummel et al, Lancet 2013; 381:
15 BENDA CHOP CVP R O R O R O MORTALITY TRIAL NOT DESIGNED to detect DIFFERENCES between the 3 chemotherapy INDUCTION regiments. Marcus et al, N Engl J Med 2017;377:
16 Cross study comparison Number of patients (n) Rate of randomized patients Stil NHL n = 122 (of 168) 73% Kluin-Nelemans et al n = 184 (of 280) 66% Remission duration B - R B R + R CHOP- R CHOP-R + R Median (months) since randomization Rate at 72 months (estimated) n.y.r. 49% 40% 12% 50% Overall Survival Median (months) since randomization Rate at 72 months (estimated) n.y.r n.y.r 64 n.y.r. 70% 66% 50% 71% After a median observation time of 4.5 years, the results are yet inconclusive Simon Rule, ASH 2016
17 R - CHOP vs R - CAP CFM ADR PRED RITUX Each 21 days 14,4 m (1) Inv: 16,1 m Inv: 30,7 m 24,7 m (1) 487 patients randomized (NO AUTO-SCT candidates) Median follow up 40 months (1) Investigator assestment: 30,7 vs 16,1 months Robak et al, N Engl J Med 2015;372:944-53
18 R-CHOP n 244 V R-CAP n 243 CR 42 % (p=0,007) CR 53 % PR 42 % PR 38 % Increased Hematologic Toxicity CHOP-R VR-CAP Platelets transfusion 3 % 23 % Grade 3 Neutropenia 67 % 85 % Grade 3 Infeccion 14 % 21 % MORE DAYS IN HOSPITAL TREATMENT Robak et al, N Engl J Med 2015;372:944-53
19 Untreated Patients 120 MEDIAN PROGRESSION FREE SURVIVAL (months) HD-ARA-C + AUTO-SCT CHOP +/- + AUTO-SCT CHOP +/- V IS IT POSSIBLE TO IMPROVE THIS RESULTS WIH BAC 500 OR LENALIDOMIDE? - CAP BENDA CHOP
20 Bendamustine results in 1º line Visco 2017 BENDA-R + ARA-C 500 (R-BAC500) MANTLE CELL LYMPHOMA: 57 patients COMPLETE REMISSION 91%, PROGRESSION 4%, Toxicity 5%. PROGRESSION FREE SURVIVAL at 35 months: 76% R-BAC500, Visco et al Lancet Haematol 2017; 4: e15 23
21 + 9 cycles Maintenance 36 cycles Phase 2. n = 38 patients Median follow-up: 30 months 85% ORR 92% (CR 64%) Grade 3 4 Adverse Events - Neutropenia (50%) - Rash (29%) - Thrombocytopenia (13%) - Anemia (11%) - Tumor flare (11%) - Fatigue (8%) months Ruan et al, N Engl J Med 2015;373:
22 Treatment V R-CAP CHOP-R BENDA-R RELAPSE
23 REFRACTORY / RELAPSE MCL
24 Chemo-Immunotherapy (R/R) Treatment n Previous Lines OR / RC (%) Median response duration Progression Free Survival BENDA-R (Phase III) Rummel et al (2016) / ,6 months GemOx-Rituximab Obrador-Hevia et al (2016) % (RC 60%) months EPOCH-Rituximab Jermann et al (2004) % (RC 28%) months HiperCVAD-R Romaguera et al (2005) % (RC 43%) months Rummel et al (2016) Lancet Oncol 2016; 17: Obrador-Hevia et al (2016) Br J Haematol Sep;174(6): Jernmann et al (2004) Ann Oncol Mar;15(3):511-6 Romaguera et al (2005) ASH Annual Meeting Abstracts; 106 [abstract 2446]
25 Old New Drugs for Relapse / Refractory n = 155 PT : 1-2 n = 54 PT : 3-4 n = 69 PT : 2-3 CR 8 % PR 25 % CR 1 % PR 20 % CR 18 % PR 41 % BORTEZOMIB TEMSIROLIMUS TEMSIROLIMUS DOR : 9,2 months PFS : 6,2 months DOR : 7,1 months PFS : 4,8 months DOR : 11 months PFS : --- months BORTEZOMIB - GEMCITABINE BORTEZOMIB - - DXM BORTEZOMIB - CHOP
26 New Drugs for Relapse / Refractory LENALIDOMIDE + / - RITUXIMAB IBRUTINIB + / - RITUXIMAB
27 Lenalidomide (R/R) More than 400 MCL included in clinical trial Good Toxicity profile. Median time to response : 2 MONTHS. TRIALS OR (%) CR/CRu (%) R. duration months Median PFS months NHL-002 (N = 15) 53 % 20 % NR NR NHL-003 (N = 57) 35 % 12 % 16.3 m 8.8 m MCL-001 (N = 134) 28 % 7% 16.6 m 4.0 m MCL-002 (N = 170) 40 % 5 % 16.1 m 8.7 m NHL-002: Wiernik et al, Journal of Clinical Oncology, 2008,26, NHL-003: Witzig et al, Annals of Oncology 22: , MCL-001 (EMERGE TRIAL): Goy et al, Journal of Clinical Oncology 31, 2013, MCL-002 (SPRINTTRIAL): Trněny, et al, Lancet Oncol 2016; 17:
28 Wang et al. UNTIL PROGRESSION Previous lines: 2 Phase 1 MTD : 20 mgrs/day Phase 2 (n=44) : ORR 57% (CR 36%, PR 21%) 19 months 11 months Wang et al, Lancet Oncol 2012; 13:
29 n = 111 patients Median previous lines: mgrs daily ORAL. CR 21 % PR 47 % Median response duration: 17 months Median time to response : 2 months Wang et al, N Engl J Med 2013;369:507-16
30 Median previous lines: 2 Median follow up: 20 months 6.2 months 14.6 months Wang patients. Median previous lines: 3 ORR: 88% (44% CR. 44% PR).
31 Refractory / Relapse MCL MEDIAN PROGRESSION FREE SURVIVAL (months) First Line 2º-3º Line 4º Line V - CAP BENDA CHOP BENDAMUSTINE GemOx EPOCH HiperCVAD IBRUTINIB LENALIDOMIDE IBRUTINIB LENALIDOMIDE TEMSIROLIMUS BORTEZOMIB TEMSIROLIMUS
32 Allogeneic Stem Cell Transplantation 2611 CIBMTR patients (62% non myeloablative) 500 MANTLE CELL LYMPHOMA. UNIQUE POTENTIALLY CURATIVE THERAPY ( 35 65% ) Urbano-Ispizua et al. Biol Blood Marrow Transplant Oct;21(10):
33 Take Home Messages - Fit patients treatment should include rituximab, cytarabine, autologous stem cell transplantation and rituximab maintenance. - There is no Gold Standard treatment for Unfit patients: R-CHOP with maintenance VR-CAP, probably with maintenance Bendamustine-R, probably without maintenance Promising results from R-BAC and Lenalidomide-Rituximab regimens - Relapsed/refractory: Immunochemotherapy (Bendamustine-R, GemOx-R, etc) IBRUTINIB +/- Rituximab Lenalidomide - Rituximab
34 Take Home Messages New therapies are NOW improving life expectancy and quality of live of this patients
35 THANK YOU FOR YOUR ATTENTION
Mantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationOptions in Mantle Cell Lymphoma Therapy
Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationLinfoma mantellare: terapia del paziente anziano. Francesco Zaja Trieste
Linfoma mantellare: terapia del paziente anziano Francesco Zaja Trieste Dramatic demographic changes Increasing proportion of elderly persons In 2015 19% of the population in the European Union were 65
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationMantle cell lymphoma-management in evolution
Review Article Page 1 of 8 Mantle cell lymphoma-management in evolution Saurabh Rajguru, Brad S. Kahl Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationManejo del linfoma de células del manto en la era de las terapias diana
Manejo del linfoma de células del manto en la era de las terapias diana Management of mantle cell lymphoma in the era of targeted drugs LINFOMA DE CÉLULAS DEL MANTO Robak T Department of Hematology, Medical
More informationLondon Cancer New Drugs Group APC/DTC Briefing
London Cancer New Drugs Group APC/DTC Briefing Rituximab for Mantle Cell Lymphoma g Contents Summary Summary & Background 1-2 Introduction 3 Discussion points/issues for Consideration 9 References 12 Background
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationMARIO PETRINI Ematologia PISA UO Ematologia - Pisa
I LINFOMI NON HODGKIN A BASSO GRADO DI MALIGNITA PESCARA 2008 linfomi mantellari MARIO PETRINI Ematologia PISA Mantle Cell Lymphoma Typical (Classic) small to medium-sized Ly with scanty cytoplasm, irregular
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 National Comprehensive Cancer Network, Inc. 2015, All
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170029P 1 NHS England INFORMATION READER BOX Directorate Medical
More informationFrontline therapy and role of high-dose consolidation in mantle cell lymphoma
MANTLE CELL LYMPHOMA Frontline therapy and role of high-dose consolidation in mantle cell lymphoma Simon Rule Department of Haematology, Derriford Hospital, Plymouth and Plymouth University Peninsula Schools
More informationRecent Advances in the Treatment of Non-Hodgkin s Lymphomas
671 Highlights of the NCCN 18th Annual Conference Recent Advances in the Treatment of Presented by Jeremy S. Abramson, MD, and Andrew D. Zelenetz, MD, PhD Abstract Non-Hodgkin s lymphomas (NHL) represent
More informationFrontline Treatment for Older Patients with Mantle Cell Lymphoma
Hematologic Malignancies Frontline Treatment for Older Patients with Mantle Cell Lymphoma HAIGE YE, a,b, AAKASH DESAI, b,c, DONGFENG ZENG, b JORGE ROMAGUERA, b MICHAEL L. WANG b a Department of Hematology,
More informationMCL comprises less than 10% of all cases of non-hodgkin
COHEN, ZAIN, AND KAHL Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies Jonathon B. Cohen, MD, Jasmine M. Zain, MD, and Brad S. Kahl, MD OVERVIEW Mantle cell lymphoma (MCL)
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationNHS England. Evidence review: Bendamustine-based chemotherapy for treatment of relapsed or refractory Mantle Cell Lymphoma (MCL)
NHS England Evidence review: Bendamustine-based chemotherapy for treatment of relapsed or refractory Mantle Cell Lymphoma (MCL) 1 NHS England Evidence review: Bendamustine-based chemotherapy for treatment
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: P
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170054P 1 NHS England INFORMATION READER BOX Directorate Medical
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationEmerging targeted therapies for follicular lymphoma A future without chemotherapy
Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationFront-line treatment in young. Role of maintenance therapy. Rome 2017 Prof Le Gouill S.
Front-line treatment in young patients with MCL: Role of maintenance therapy Rome 2017 Prof Le Gouill S. Is there a need for maintenance for young MCL patients? Is there a need for maintenance for young
More informationCurrent and Emerging Therapies in Mantle Cell Lymphoma
Current Treatment Options in Oncology (2013) 14:198 211 DOI 10.1007/s11864-013-0230-z Lymphoma (LI Gordon, Section Editor) Current and Emerging Therapies in Mantle Cell Lymphoma L. Kyle Brett, MD Michael
More informationMantle Cell Lymphoma: Paradigm Shift?
Mantle Cell Lymphoma: Paradigm Shift? Andre Goy, MD Chairman, John Theurer Cancer, Hackensack, NJ Lydia Pfund Chair for Lymphoma Chief Science Officer, Director of Research and Innovation for RCCA Professor
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationMantle cell lymphoma: The promise of new treatment options
Critical Reviews in Oncology/Hematology 80 (2011) 69 86 Mantle cell lymphoma: The promise of new treatment options Andre Goy a,, Brad Kahl b a Lymphoma Division, John Theurer Cancer Center, Hackensack
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma. Reference: NHS England 1630
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma Reference: NHS England 1630 1 First published: TBC Prepared by NHS England Specialised
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology December 2013 Integrating Emerging Treatment Options in Mantle Cell Lymphoma Moderator Discussants Brad S. Kahl, MD Skoronski Chair
More informationMantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care? Authors: *Susmita Sharma, 1 John W. Sweetenham 2 1. Department of Hematology/Oncology, Huntsman Cancer Institute, University of Utah,
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationClinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages) NHS England Reference: 17088P NHS England INFORMATION READER BOX Directorate Medical
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) FOLL-B category designation for first-line therapy options for FL: Bendamustine + rituximab RCHOP RCVP Submission from Genentech to review the data related to obinutuzumab for
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationMANTLE CELL LYMPHOMA MTOR-INHIBITION
MANTLE CELL LYMPHOMA MTOR-INHIBITION Rome, 23. March 2017 Prof. Dr. med. Georg Heß III. Med. Klinik Universitäres Centrum für Tumorerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationMarked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.
Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Abrahamsson, Anna; Dahle, Nina; Jerkeman, Mats Published in: Leukemia & lymphoma
More informationTransformed lymphoma: biology and treatment
Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationFrontline Therapy in Mantle Cell Lymphoma: New Standards in 2017
Frontline Therapy in Mantle Cell Lymphoma: New Standards in 2017 Morgane Cheminant, MD, and Olivier Hermine, MD, PhD Abstract Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by the t(11;14)
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationHannover-Meeting Niedrig-malignes NHL. Prof. C. Buske Medizinische Klinik III Klinikum Großhadern LMU München
Hannover-Meeting 2009 Niedrig-malignes NHL Prof. C. Buske Medizinische Klinik III Klinikum Großhadern LMU München Follikuläres Lymphom Konzepte Wenn wir behanden müssen was sollen wir initial dem Patienten
More informationClinical Commissioning Policy: Bortezomib for relapsed/refractory mantle cell lymphoma (all ages) NHS England Reference: P
Clinical Commissioning Policy: Bortezomib for relapsed/refractory mantle cell lymphoma (all ages) NHS England Reference: 1735P NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationTraditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies
More informationPeripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation
Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationMantle Cell Lymphoma Management Updates 2017
Mantle Cell Lymphoma Management Updates 2017 Robert Chen, MD Associate Professor Associate Director of Toni Stephenson Lymphoma Center City of Hope DISCLOSURES I am a consultant for BMS, Merck, Seattle
More informationGuideline for the management of mantle cell lymphoma
guideline Guideline for the management of mantle cell lymphoma Pamela McKay, 1 Mike Leach, 1 Bob Jackson, 2 Stephen Robinson 3 and Simon Rule 4 1 Department of Haematology, Beatson West of Scotland Cancer
More informationLenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
The new england journal of medicine Original Article Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma Jia Ruan, M.D., Ph.D., Peter Martin, M.D., Bijal Shah, M.D., Stephen J. Schuster,
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationNovita da EHA 2016 Copenhagen Linfomi
Firenze, 16th September 2016 Marco Ladetto MD, Az Osp Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy EU Novita da EHA 2016 Copenhagen Linfomi THREE QUESTIONS TO ADDRESS: 1. Is ASCT still the
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationLow grade Non-Hodgkin Lymphoma: New Therapies & Updates
Low grade Non-Hodgkin Lymphoma: New Therapies & Updates Craig A. Portell MD Assistant Professor of Medicine ivision of Hematology/Oncology University of Virginia Friday, April 28, 2017 Disclosures I have
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationUpdate on Waldenström Macroglobulinemia (WM)
Update on Waldenström Macroglobulinemia (WM) Stephen M. Ansell, MD, PhD Professor of Medicine Division of Hematology Mayo Clinic Rochester, MN Update on Waldenström Macroglobulinemia (WM) Disclosures Stephen
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationNewly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 28 (Supplement 4): iv62 iv71, 2017 doi:10.1093/annonc/mdx223 CLINICAL PRACTICE GUIDELINES Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis,
More information